ADC Therapeutics SA
World Rank (Jan-05-2024)
19,359
Market Cap (Jan-05-2024)
0.152 Billion USD
World Rank (Jul-30-2023)
21,504
Market Cap (Jul-30-2023)
0.103 Billion USD
World Rank (Dec-25-2022)
16,329
Market Cap (Dec-25-2022)
0.273 Billion USD
World Rank (Jan-07-2022)
7,370
Market Cap (Jan-07-2022)
1.52 Billion USD
Annual Revenue in USD
0 Million USD
Annual Net Income in USD
-246 Million USD
Annual Results for Period Ending
Dec-2020 ending year
Company Profile
ADC Therapeutics is a Clinical Stage Oncology Biotechnology company, development and commercialization of next generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology. The headquarters is in Switzerland.
Facts About Company
ADC Therapeutics company annual revenue was 209 million USD and annual net loss was -155 million USD as on Dec-2022.
Company Website